Clinical Trials Logo
  1. Home
  2. Substance Withdrawal Syndrome
  3. NCT00980044

Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal

Substance Withdrawal Syndrome Clinical Trial

Official title:
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal

Clinical Trial Summary

Prescription opioid addiction is a growing public health problem and more pharmacologic treatments are needed because current approved medications have had limited patient acceptance (naltrexone), limited availability (methadone), and concerns about misuse and diversion (methadone and buprenorphine). Tramadol is a currently approved medication used to treat moderate-severe pain, and initial studies demonstrate that it may be useful for treatment of the uncomfortable syndrome of opioid withdrawal without producing euphoric effects. This study will determine whether two different doses of extended release tramadol can treat opioid withdrawal and whether tramadol itself produces withdrawal after it is no longer taken.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00980044
Study type Interventional
Source University of Kentucky
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 2009
Completion date March 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT00114439 - Lithium Cannabis Withdrawal Study Phase 2
Completed NCT02643355 - Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED N/A
Completed NCT02782156 - Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT N/A
Recruiting NCT00792415 - Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool N/A
Completed NCT02431728 - The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Phase 1/Phase 2
Completed NCT00695864 - Effect of Ondansetron for Withdrawal Symptoms N/A
Active, not recruiting NCT02951793 - Abuse and Addiction in ICU
Completed NCT02108626 - Electronic Cigarettes in Daily Dependent Smokers Phase 4
Recruiting NCT04917185 - EA for PAAS: A pRCT N/A
Completed NCT02801357 - Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Phase 1
Completed NCT01362959 - Nicotine Replacement Therapy in the Intensive Care Unit Phase 4
Completed NCT00992979 - Therapeutic Massage to Manage Withdrawal Related Anxiety Phase 2
Completed NCT02825459 - Does Abstinence From E-cigarettes Produce Withdrawal Symptoms? N/A
Completed NCT00900900 - The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers Phase 2
Completed NCT02318290 - Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study N/A
Completed NCT00032968 - Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Phase 3
Completed NCT03374722 - Opioid Withdrawal Symptoms in Critically Ill Patients
Completed NCT03435614 - Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Completed NCT00570219 - The Effect of Valproate on Benzodiazepine Withdrawal Severity N/A
Completed NCT00367874 - Treatment of Polydrug-Using Opiate Dependents During Withdrawal Phase 4